



## Mesa 2


# Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study (ERS)

Claus Vogelmeier, Leonardo M. Fabbri, Susan Bell, Kay Tetzlaff,  
Helgo Magnussen, Henrik Watz




The NEW ENGLAND  
JOURNAL of MEDICINE

Hurst JR, Vestbo J, Arzoo A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *New England Journal of Medicine*. 2010;363:1128-1138.



**Figure 1** Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients with 1–2 acute exacerbations of COPD requiring hospital management; group C, patients with  $\geq 3$  acute exacerbations of COPD.




**Figure 2** Patients with 0, 1 or 2 exacerbations requiring hospital management


Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salazar A, Garcia-Renaudo G, Ramirez J, et al. Exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2000;162:1267-1272.



ORIGINAL ARTICLE


# Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD






# Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study (ERS)

Claus Vogelmeier, Leonardo M. Fabbri, Susan Bell, Kay Tetzlaff, Helgo Magnussen, Henrik Watz






## Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial

Henrik Watz, Kay Tetzlaff, Emiel F M Wouters, Anne Kirsten, Helgo Magnussen, Roberto Rodriguez-Roisin, Claus Vogelmeier, Leonardo M Fabbri, Pascal Chanez, Ronald Dahl, Bernd Disse, Helen Finnigan, Peter M A Calverley

A	n		Rate ratio (95% CI)	p value
<b>Total</b>	2296		1.10 (0.96-1.26)	0.17
<b>Baseline eosinophils (&lt;2% vs ≥2%)</b>				
<2%	1039		1.02 (0.83-1.25)	0.84
≥2%	1200		1.22 (1.02-1.48)	0.033
<b>Baseline eosinophils (&lt;3% vs ≥3%)</b>				
<3%	1520		1.07 (0.90-1.26)	0.46
≥3%	719		1.27 (1.00-1.62)	0.053
<b>Baseline eosinophils (&lt;4% vs ≥4%)</b>				
<4%	1803		1.03 (0.89-1.20)	0.66
≥4%	436		1.63 (1.19-2.24)	0.0025
<b>Baseline eosinophils (&lt;5% vs ≥5%)</b>				
<5%	1962		1.07 (0.92-1.23)	0.39
≥5%	277		1.82 (1.20-2.76)	0.0049
<b>Baseline eosinophils (&lt;6% vs ≥6%)</b>				
<6%	2060		1.10 (0.95-1.27)	0.20
≥6%	179		1.50 (0.92-2.44)	0.11



## **Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study (ERS)**

Claus Vogelmeier, Leonardo M. Fabbri, Susan Bell, Kay Tetzlaff, Helgo Magnussen, Henrik Watz

### Conclusiones:

- Resultados que apoyan a los de ECLIPSE (tandas antibióticos o corticoides)
- Probablemente los que tomaban CI eran más exacerbadores o más graves que los que no los tomaban o los tenían puestos por eosinofilia relevante
- Sujetos con mejor FEV1% o en GOLD C se exacerbaban menos (¿relación con los síntomas o sólo con el FEV1%?)